Future Directions in Vitiligo: Emerging Therapies and Patient-Centered Care

This episode, titled Future Directions in Vitiligo: Emerging Therapies and Patient-Centered Care, features Dr. Desai discussing the following critical questions:

Which investigational agents are you excited about for vitiligo?

How do you see the future of vitiligo evolving over the next 5 years, what is the role of patient advocacy groups, and what are your key takeaways?

Several investigational agents are generating excitement in vitiligo, including systemic JAK inhibitors like upadacitinib, next-generation topical JAK inhibitors, and combination therapies designed to enhance repigmentation and durability of response. Over the next five years, the treatment landscape is expected to evolve toward more personalized approaches, targeting both the immune pathways driving melanocyte destruction and the practical needs of patients with varying disease extent. Patient advocacy groups will play an increasingly important role in raising awareness, supporting access to therapies, and providing education and psychosocial support. Key takeaways highlight the importance of early intervention, long-term adherence, and integrating emerging therapies to improve both clinical outcomes and patients’ quality of life.

Throughout the conversation, Dr. Desai provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.